Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

241P - Single-cell RNA analysis uncovers tumor microenvironment heterogeneity and underlying mechanisms for imatinib resistance in gastrointestinal stromal tumor

Date

27 Jun 2024

Session

Poster Display session

Presenters

Ping Tao

Citation

Annals of Oncology (2024) 35 (suppl_1): S94-S105. 10.1016/annonc/annonc1479

Authors

P. Tao1, Z. Wang2, J. Wang3, L. Ma4, Y. Zhang3, H. Tong3

Author affiliations

  • 1 Shanghai TCM-Integrated Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai/CN
  • 2 Jinshan Hospital of Fudan University, Shanghai/CN
  • 3 Zhongshan Hospital Affiliated to Fudan University, Shanghai/CN
  • 4 Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 241P

Background

The tumor microenvironment (TIME) directly determines patients' therapeutic efficiencies and clinical outcomes. An in-depth and systemic understanding of the TIME is required to improve the prognosis of patients with gastrointestinal stromal tumor (GIST).

Methods

This study conducted single-cell RNA sequencing of eight-paired tumors and adjacent normal tissues to map the GIST immune landscape, and validated in two independent cohorts [cohort-ZSFD (n=65) and cohort- GSE136755 (n=65)] from the largest sarcoma research center of East China and GEO database, respectively.

Results

T cells, NK cells, B cells and macrophages were highly enriched in the tumor area and transitioned from cytotoxic to exhaustion phenotypes. This study also revealed tumor- specific germinal center B (GC-B) cells associated with tertiary lymphoid structure (TLS). Imatinib sensitive GIST was identified by enriched B cell signature, especially with the IgA+ plasma cell (PC) signature, while the resistant group enriched with cancer related fibroblast (CAF) signature. IgG+ PC had a high potential to extensively interact with SPP1+ TAMs through a significantly enriched ligand-receptor pair in CCL2-CCR2. Combined with transcriptome data, the GIST immune classes (GICs: A-C) was constructed by eight immune cell types and two stroma components through ssGSEA method. A high proportion of GC-B cell and IgG+PC, as well as GIC-C in GIST was predictive of favorable clinical outcomes and associated with elevated hormonal immune responses.

Conclusions

Our study depicts an immune-excluded stromal landscape of TIME ecosystem, and offers valuable insights for its connection with antitumor response and paves the way for potential markers of efficacy evaluation and imatinib resistance in GIST.

Legal entity responsible for the study

H. Tong.

Funding

National Natural Science Foundation of China (81802302); Scientific Research Project of Shanghai Municipal Health Commission (20214Y0087, 20204Y0409); Hongkou District Clinical Medicine Outstanding Young Talents Training Program (No. HKLCYQ2024-01); "Young Talents" Training Plan of Shanghai TCM-integrated Hospital (No. RCPY0063); Scientific Research Project of Shanghai TCM-integrated Hospital (No. 18-01-03); Scientific Research Project of Hongkou District Health Committee (No. 2302-02, No. 2003-02); Natural Science Foundation of Fujian province (No. 2023J011698); Natural Science Foundation of Xiamen City (No. 3502Z20227279).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.